Silverback Current Deferred Revenue from 2010 to 2025
| SPRY Stock | 12.57 0.39 3.20% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 3.6 K | Current Value 3.4 K | Quarterly Volatility 1.6 M |
Check Silverback Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Silverback Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 62.4 K, Other Operating Expenses of 81.6 M or Research Development of 20.8 M, as well as many indicators such as Price To Sales Ratio of 16.4 K, Dividend Yield of 0.0 or PTB Ratio of 2.14. Silverback financial statements analysis is a perfect complement when working with Silverback Therapeutics Valuation or Volatility modules.
Silverback | Current Deferred Revenue |
Latest Silverback Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Silverback Therapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Silverback Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Silverback Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Silverback Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 2,528,064 | |
| Geometric Mean | 784,884 | |
| Coefficient Of Variation | 61.35 | |
| Mean Deviation | 1,361,162 | |
| Median | 3,518,000 | |
| Standard Deviation | 1,551,018 | |
| Sample Variance | 2.4T | |
| Range | 3.5M | |
| R-Value | (0.82) | |
| Mean Square Error | 864.4B | |
| R-Squared | 0.66 | |
| Significance | 0.0001 | |
| Slope | (265,591) | |
| Total Sum of Squares | 36.1T |
Silverback Current Deferred Revenue History
About Silverback Therapeutics Financial Statements
Silverback Therapeutics investors use historical fundamental indicators, such as Silverback Therapeutics' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Silverback Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 3.6 K | 3.4 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Silverback Stock Analysis
When running Silverback Therapeutics' price analysis, check to measure Silverback Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silverback Therapeutics is operating at the current time. Most of Silverback Therapeutics' value examination focuses on studying past and present price action to predict the probability of Silverback Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silverback Therapeutics' price. Additionally, you may evaluate how the addition of Silverback Therapeutics to your portfolios can decrease your overall portfolio volatility.